The published circulating microRNA (miRNA) signatures proposed for early-stage non-small cell lung cancer (NSCLC) detection are inconsistent and difficult to replicate. Reproducibility and validation of a miRNA simple signature of NSCLC are prerequisites for translation to clinical application.
Serum miR-223: a validated biomarker for detection of early-stage non-small cell lung cancer
Poli, Albino;Moretti, Francesca;
2019-01-01
Abstract
The published circulating microRNA (miRNA) signatures proposed for early-stage non-small cell lung cancer (NSCLC) detection are inconsistent and difficult to replicate. Reproducibility and validation of a miRNA simple signature of NSCLC are prerequisites for translation to clinical application.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
